Last updated: February 22, 2026
What is NDC 64764-0677?
NDC 64764-0677 refers to a specific drug product listed in the National Drug Code (NDC) database. Based on available data, this code likely corresponds to a branded or generic pharmaceutical product; however, detailed specifics such as active ingredients, formulation, manufacturer, and approval status require further verification.
Market Landscape Overview
Product Classification
- Therapeutic area: The drug's therapeutic category influences competitive positioning. Its market depends on its indication—whether it targets chronic conditions, acute illnesses, or specialty segments.
- Approval status: FDA approval confers market exclusivity or generic competition. For newly approved drugs, launch dates influence market size estimates.
- Manufacturers: Market share distribution hinges on whether the product is branded or generic.
Competitive Environment
- Direct competitors: Drugs with similar active ingredients or therapeutic effects.
- Market penetration: Estimated based on prevalence in approved indications, prescriber acceptance, insurance coverage, and reimbursement policies.
- Pipeline influence: Pending generics or biosimilars may impact future pricing and volume.
Regulatory Considerations
- Any recent FDA action, such as approvals or label expansions, can alter market dynamics.
- Patent status and exclusivity periods set baseline expectations for initial price points and generic entry.
Pricing Dynamics
Current Price Benchmarks
- Average Wholesale Price (AWP): Published in drug compendia; often the starting point.
- Average Sales Price (ASP): Used for Medicare reimbursement, reflects actual sale prices.
- Retail price: Over-the-counter or pharmacy list prices influence consumer costs.
- Reimbursement levels: Managed care contracts and insurer negotiations shape effective prices.
Price Trends
- Brand vs. generic: Brand drugs typically command higher prices—often 2–10 times higher than generics.
- Market penetration: Early market entry usually involves premiums; prices tend to decrease over time with generic competition.
- Pricing strategies: List prices often remain stable initially; discounts, rebates, and patient assistance programs impact net prices downward.
Comparable Drugs Pricing
| Drug Name |
Indication |
Market Price (Wholesale) |
Date of Price Data |
| Example A |
Chronic Condition |
$X per unit |
MM/YYYY |
| Example B |
Acute Condition |
$Y per unit |
MM/YYYY |
Note: Specific current prices for NDC 64764-0677 require proprietary databases or direct cost data.
Projections for Price Evolution
Short-Term (1–2 years)
- If the product is newly approved, initial list prices will reflect the branded market level—typically $X–$Y per unit.
- Entry of generics expected within 12–24 months can reduce prices by 50–70%.
- Reimbursement rates will adjust according to insurer negotiations and formulary placements.
Medium to Long-Term (3–5 years)
- Brand prices may stabilize or marginally decrease as generic competition intensifies.
- Potential for price increases if the drug demonstrates superior efficacy or added indications.
- Price erosion is likely, with average reductions of 20–40% upon generic entry.
Market Size & Volume Projections
- Influenced by disease prevalence, geographic coverage, and payer policies.
- Market penetration often grows in the initial years, plateauing after generic competition.
Implications for Stakeholders
- Pharmaceutical companies: Price setting strategies must account for patent expirations, competitive launches, and payer negotiations.
- Investors: Timing of patent protections and upcoming generic launches are critical to valuation.
- Healthcare providers: Cost-effectiveness influences formulary decisions and prescribing patterns.
References
- U.S. Food and Drug Administration. (2022). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.fda.gov/drugs/therapeutic-equivalence
- IQVIA. (2022). National Prescription Audit data.
- SSR Health. (2022). Drug Pricing Trends.
- Medicare. (2022). ASP Pricing Data.
Key Takeaways
- Exact data on NDC 64764-0677’s indication and pricing are proprietary; general market trends apply.
- Pricing will start at a brand premium, declining with the arrival of generics.
- Market size depends on the therapeutic area, with favorable conditions leading to higher pricing and sales volume.
- Payer negotiations and formulary placement heavily influence net prices.
- Patent status and competitive pipeline shape long-term price projections.
FAQs
1. How soon can generic versions of NDC 64764-0677 be expected?
If the product is recently approved, a generic competitor might launch within 12–24 months post-patent expiry, depending on patent challenges and regulatory pathways.
2. What factors impact the initial pricing of this drug?
Market exclusivity, manufacturing costs, perceived therapeutic value, and formulary positioning influence initial list prices.
3. How do rebates and discounts affect the real market price?
Rebates negotiated with payers and pharmacy benefit managers reduce the net price paid by insurers and ultimately impact patient out-of-pocket costs.
4. What is the typical pricing trend after patent expiration?
Average prices tend to drop 50–70% within the first year of generic entry, stabilizing at lower levels over subsequent years.
5. How does market size influence future pricing?
Larger patient populations and broader indication approvals generally justify higher prices and support sustained revenues.
[1] U.S. Food and Drug Administration. (2022). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
[2] IQVIA. (2022). National Prescription Audit data.
[3] SSR Health. (2022). Drug Pricing Trends.
[4] Medicare. (2022). ASP Pricing Data.
